VITAL MEDSPA
Peptide Therapy in Hallandale Beach
Explore peptide therapy consultations in Hallandale Beach at VITAL MedSpa. Your provider reviews your health history, medications, and goals, and discusses the available evidence, potential risks, and alternatives for any proposed treatment. Recommendations depend on the specific medication and clinical indication; a consultation does not guarantee a prescription or a particular result.
Why Choose VITAL MedSpa for Peptide Therapy?
At VITAL MedSpa, care begins with an individualized review of your health history, medications, and treatment goals. Your provider explains the clinical purpose, available evidence, limitations, potential risks, and alternatives for any proposed medication. If treatment is recommended, your plan includes instructions and appropriate follow-up to review your response and any concerns. Recommendations are based on clinical findings rather than a one-size-fits-all protocol.
How Our Peptide Therapy Program Works
In-depth Health Assessment
Your consultation includes a review of your health history, current medications, symptoms, and treatment goals. Your provider determines whether a physical assessment or laboratory testing is needed and considers relevant precautions before discussing treatment options. This evaluation helps guide recommendations; it does not mean that a peptide medication will be appropriate or prescribed.
Customized Peptide Plan
If a medication is recommended, your provider explains its intended use, available evidence, potential benefits, risks, and alternatives. Your individualized plan includes administration instructions and appropriate monitoring. The choice of medication depends on your clinical needs and the specific treatment being considered, rather than a standard blend of peptides for every patient.
Ongoing Support & Accountability
Follow-up appointments allow your provider to review your treatment response, any side effects, and relevant laboratory results when needed. This information helps determine whether treatment should continue, change, or stop. Your provider also reviews administration instructions and explains when to contact the clinic between visits. The follow-up schedule depends on the medication and your individual circumstances.
Interested in how peptides may relate specifically to weight management? Read our guide to peptide therapy for weight loss, including evidence, safety considerations, and how peptide-based options compare with GLP-1 medications.
Our Range of Peptide Therapies
The compounds listed below differ in their intended uses, clinical evidence, potential risks, and regulatory status, and not all are peptides. Your provider discusses these distinctions and medically appropriate alternatives during your consultation. Inclusion on this page does not establish that a compound is safe, effective, approved, or suitable for your care.
CJC-1295 has been studied for its effects on growth hormone release. Human clinical data are limited, and it should not be presented as a proven treatment for anti-aging, fat loss, sleep, or cognitive improvement.
FDA has identified potential safety concerns, including unwanted immune responses and serious reported adverse events such as increased heart rate and systemic vasodilatory reactions. Discuss these uncertainties and established treatment alternatives with your provider.
FDA-approved tesamorelin has a specific indication for reducing excess abdominal fat in adults with HIV and lipodystrophy. This indication should not be generalized to routine weight loss, anti-aging, improved sleep, cognitive enhancement, muscle toning, or increased vitality.
Tesamorelin can increase IGF-1 levels and requires appropriate medical evaluation and monitoring. Potential concerns include glucose intolerance, fluid retention, hypersensitivity, injection-site reactions, and risks related to malignancy. Your provider should review the intended use, evidence, contraindications, and established alternatives before considering treatment.
Retatrutide is an investigational medication being studied in Phase 3 clinical trials for obesity and related metabolic conditions. Research has evaluated its activity at three hormone receptors, but results should not be presented as guaranteed or as a routine treatment outcome.
Because retatrutide remains under clinical evaluation, this page should not promise rapid weight loss, appetite control, improved energy, or prevention of weight regain. Your provider can discuss approved treatment options, eligibility, potential risks, and alternatives based on your health history and goals.
MOTS-c is an experimental mitochondrial-derived peptide studied primarily in laboratory and preclinical research related to cellular metabolism. Human safety and effectiveness data remain limited, so it should not be described as a proven treatment for energy, fat loss, exercise performance, longevity, or insulin sensitivity.
The FDA has identified potential safety concerns for compounded MOTS-c, including possible immune reactions and insufficient human exposure data to establish safety. A consultation should address these uncertainties and approved or better-established alternatives rather than promise a specific outcome.
AOD-9604 is a modified peptide fragment studied for possible effects on fat metabolism. Available evidence is limited, and it should not be described as a proven or guaranteed treatment for fat loss, blood-sugar control, exercise recovery, joint health, or body composition.
The FDA has identified potential safety concerns for compounded AOD-9604, including possible immune reactions, impurities, and limited clinical data. A consultation should review the uncertainty, potential risks, and established alternatives before any treatment decision.
Sermorelin is a synthetic analogue of growth hormone–releasing hormone that stimulates the pituitary gland to release growth hormone. Its effects depend on the patient and clinical context, and it should not be presented as a proven treatment for anti-aging, fat loss, muscle gain, improved sleep, immunity, cognition, skin rejuvenation, or faster injury recovery.
Any proposed use requires individualized medical evaluation and appropriate monitoring. Your provider should explain the intended use, limitations of the evidence, possible effects involving the growth hormone and IGF-1 pathways, potential risks, and established alternatives before treatment is considered.
Oxytocin is a naturally occurring hormone and prescription medication. FDA-labeled oxytocin products are injections used for specific obstetric indications; those indications should not be generalized to compounded intranasal oxytocin or presented as established treatment for bonding, anxiety, mood, libido, or social confidence.
Evidence for intranasal use in wellness settings is limited, and outcomes may vary. A clinician should review the intended purpose, available evidence, contraindications, interactions, and potential adverse effects before considering use, without promising emotional, relationship, sexual, or cognitive benefits.
Products marketed as Pentadeca Arginate or BPC-157–related compounds should not be assumed to contain interchangeable active ingredients. Human evidence remains limited, and these compounds should not be described as proven to accelerate healing, relieve pain, repair the digestive system, improve blood flow, or support nervous-system recovery.
The FDA has reported insufficient clinical safety information for BPC-157–related substances and potential concerns involving immune reactions, aggregation, peptide-related impurities, and product characterization. The exact ingredient and formulation must be verified, and a clinician should discuss these uncertainties and established alternatives before considering treatment.
NAD+ is a coenzyme involved in cellular energy metabolism; it is not a peptide. Its biological role does not establish injectable or infused NAD+ as a proven treatment for fatigue, cognitive decline, aging, detoxification, mood, weight loss, or immune support. Clinical evidence for these broad wellness claims remains limited.
The FDA has received reports of severe chills, shaking, vomiting, and fatigue following the use of injectable NAD+ products, with some patients requiring medical treatment. Any proposed use requires individualized clinical evaluation, discussion of the evidence and risks, and appropriate controls for the quality and sterility of compounded products.
Tirzepatide is a prescription medication. FDA-approved products containing tirzepatide have specific indications for type 2 diabetes and chronic weight management in eligible adults. Approval applies to those products and does not automatically extend to a compounded formulation. Weight-management treatment is used together with a reduced-calorie diet and increased physical activity, and individual results vary.
Treatment requires medical evaluation and follow-up. Common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort, with additional warnings and contraindications reviewed by your provider. Tirzepatide should not be promoted as a rapid or guaranteed weight-loss solution or as a general energy or metabolism booster.
TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4; it is not equivalent to the complete thymosin beta-4 molecule. The FDA has not identified clinical studies or human exposure data for TB-500 administered by any route. Claims that it accelerates wound healing, repairs muscles or joints, reduces inflammation, promotes blood-vessel growth, or supports cardiac recovery are not established.
Potential risks in humans remain unknown. The FDA has also identified concerns involving immune reactions, peptide aggregation, impurities, and inconsistent product characterization. These uncertainties and established treatment alternatives should be reviewed before considering its use.
MIC + B12 is a compounded combination that typically contains methionine, inositol, choline, and vitamin B12; it is not a peptide. Although these nutrients participate in normal cellular processes, that does not establish MIC + B12 injections as a proven treatment for burning fat, detoxifying the liver, lowering cholesterol, improving mood, increasing energy, or enhancing hair, skin, and nails.
Vitamin B12 treatment may be appropriate for a documented deficiency or certain clinical conditions. A provider should verify the ingredients, determine whether there is a medical need, and explain the limited evidence, possible adverse reactions, and quality considerations associated with a compounded injectable product.
Bremelanotide is a prescription medication. The FDA-approved product is indicated specifically for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women after other contributing causes have been evaluated. It is not indicated for men, postmenopausal women, erectile dysfunction, or enhancement of sexual performance. Approval of the branded product does not automatically extend to compounded formulations.
Bremelanotide can temporarily increase blood pressure and reduce heart rate. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. A clinician should review cardiovascular history, medications, potential adverse effects, and whether the patient meets the approved indication before considering treatment.
GHK-Cu is a copper-binding peptide studied in laboratory, preclinical, and cosmetic contexts. Findings involving topical or experimental use should not be generalized to injectable GHK-Cu or presented as proof that it regrows hair, accelerates wound healing, improves cognition, reduces systemic inflammation, or promotes longevity.
The FDA reports that compounded injectable GHK-Cu may pose a risk of immune reactions because of possible peptide aggregation and impurities, and human safety data are limited. The formulation and route of administration matter, and a clinician should explain the available evidence, uncertainties, potential risks, and established alternatives before considering treatment.
Selank is a synthetic peptide studied for possible effects on the nervous system, but available human evidence remains limited. It should not be described as a proven treatment for anxiety, stress, depression, mood, focus, memory, or neuroprotection, or as guaranteed to be non-sedating, non-addictive, or free of withdrawal effects.
The FDA reports that compounded selank acetate may pose a risk of immune reactions because of possible aggregation and peptide-related impurities, and important human safety information is lacking. Mental-health symptoms require an appropriate clinical evaluation and discussion of evidence-based treatment alternatives.
5-Amino-1MQ is an experimental small molecule, not a peptide. Available human clinical evidence does not establish it as a safe and effective treatment for increasing metabolism, reducing body fat, improving insulin sensitivity, preserving muscle, enhancing mitochondrial function, or promoting longevity.
The FDA has raised regulatory concerns about compounded products made with 5-Amino-1MQ, including its ineligibility for compounding exemptions under section 503B. It should not be marketed as an established or routine therapy. A clinician should explain the limited evidence, unknown risks, regulatory status, and approved or better-established alternatives.
Melanotan I is commonly used as a name for afamelanotide or related products. FDA approval applies specifically to the SCENESSE 16 mg implant, which is indicated to increase pain-free light exposure in adults with erythropoietic protoporphyria. That approval does not extend to compounded or other formulations marketed for cosmetic tanning, vitiligo, mood, or libido.
Melanotan I should not be promoted as producing a safe tan, preventing sunburn, or protecting the skin from ultraviolet damage. The exact product and formulation must be identified and reviewed by a qualified clinician, and appropriate sun-protection practices and skin monitoring remain necessary.
Tesofensine is an investigational small-molecule drug, not a peptide. Although it has been studied for weight management, it should not be presented as a proven or routine treatment for suppressing appetite, accelerating metabolism, improving mood or cognition, controlling glucose, or preventing weight regain.
Clinical research has reported potential effects on heart rate, blood pressure, sleep, mood, and other adverse reactions. FDA has also stated that tesofensine is ineligible for use in human drug compounding under section 503A. Patients should discuss the limited evidence, regulatory status, potential risks, and approved weight-management alternatives with a qualified clinician.
Glutathione is a naturally occurring tripeptide involved in the body’s antioxidant processes. Its biological role does not establish injectable or infused glutathione as a proven treatment for detoxification, skin brightening, immune enhancement, chronic-disease prevention, increased energy, or improved recovery.
The formulation and route of administration require careful review. FDA has reported serious reactions associated with contaminated glutathione used in compounded sterile injections, including breathing difficulty, low blood pressure, fever, chills, and hospitalization. Any proposed use requires clinical evaluation and appropriate controls for product quality and sterility.
SLU-PP-332 is an experimental small molecule, not a peptide. Published studies examining its effects on exercise endurance, energy expenditure, fat metabolism, insulin sensitivity, and mitochondrial activity have primarily involved laboratory models and mice. These findings do not establish safety or effectiveness in humans.
SLU-PP-332 should not be promoted as a treatment for weight loss, metabolic disease, muscle preservation, or as a substitute for exercise. Human dosing, adverse effects, drug interactions, and long-term risks have not been established, and it should not be presented as a clinical wellness treatment outside appropriately authorized research.
Semax is a synthetic heptapeptide studied for possible neurological effects, but available human evidence remains limited. It should not be presented as a proven treatment for improving focus, memory, mood, mental performance, neuroprotection, or recovery from stroke or brain injury.
FDA considers semax and semax acetate insufficiently characterized and has identified potential immunogenicity concerns for compounded nasal sprays because of possible peptide aggregation and impurities. Important information about product quality and human safety remains limited. Patients with cognitive, neurological, or mental-health symptoms should receive an appropriate clinical evaluation and discuss established treatment alternatives.
What can we help you find?
Find answers to common questions about our peptide therapy consultations and personalized treatment plans.
Peptide therapy is a broad term used for treatments involving short chains of amino acids that may interact with specific biological pathways. However, each medication has a different mechanism, level of evidence, safety profile, and regulatory status, and some compounds marketed in this category are not peptides at all.
A consultation should focus on the specific medication being considered, its intended clinical purpose, available evidence, potential risks, and approved alternatives. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before being marketed.
Candidacy depends on the specific medication, clinical indication, available evidence, and your individual health profile. Your provider will review your symptoms, medical history, current medications, allergies, relevant laboratory results, and potential contraindications before discussing any treatment.
Not every compound is appropriate for every patient, and some may not be recommended because of limited evidence, safety concerns, regulatory status, or the availability of an FDA-approved alternative. Completing a consultation does not guarantee that a medication will be prescribed.
There is no universal timeline. The response depends on the specific medication, reason for treatment, route of administration, treatment plan, and individual health factors. Some patients may not experience the desired benefit.
Your provider will explain what can reasonably be monitored, when follow-up is appropriate, and when treatment should be adjusted or discontinued. Results should not be guaranteed, and changes to a prescribed plan should only be made with clinical guidance.
The options discussed during a consultation depend on the patient’s clinical needs and may include FDA-approved medications, compounded preparations, or a discussion of investigational compounds and established alternatives. The products shown on this page do not all belong to the same drug class, and several are not peptides.
Listing a compound does not mean that it is currently available, FDA-approved, appropriate for treatment, or recommended for every patient. Your provider will explain the evidence, regulatory status, potential risks, and alternatives associated with any specific option.
Potential side effects and serious risks vary significantly by medication, formulation, route of administration, dose, and individual health history. Before treatment, your provider should review the known risks, contraindications, medication interactions, and warning signs associated with the specific product being considered.
Compounded medications can also present quality concerns because FDA does not review them for safety, effectiveness, or quality before marketing. Contact your provider if you develop new or worsening symptoms, and seek urgent medical attention for signs of a severe reaction.
The route of administration depends on the specific medication and formulation and may differ substantially between products. If treatment is prescribed, your provider will give product-specific instructions. Do not change the dose, schedule, route, or storage conditions without clinical guidance.
Follow-up is individualized and may include reviewing symptoms, adverse effects, medication use, vital signs, or laboratory results when clinically appropriate. Treatment may be adjusted or discontinued if the expected benefit is not observed or if safety concerns arise.